Tebentafusp for Uveal Melanoma

Source: OncLive, July 2021

Richard D. Carvajal, MD: Let’s shift gears to tebentafusp, an immunotherapy where there is clear success. I wonder if you can describe for the audience how this drug works? What’s its mechanism?

Marlana M. Orloff, MD: Yes, it goes by a couple of different names now: an ImmTAC or an immune mobilizing monoclonal T-cell receptor against cancer, or simply kind of a TCR [T-cell receptor], but the way that I like to describe it is that it’s like a magnet.

READ THE ORIGINAL FULL ARTICLE